Nanobiotix SA
PAR:NANO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NANO's latest stock split occurred on Feb 25, 2014
The company executed a 572-for-523 stock split, meaning that for every 523 shares held, investors received 572 new shares.
Before the split, NANO traded at 20.6 per share. Afterward, the share price was about 18.95.
The adjusted shares began trading on Feb 25, 2014. This was the only stock split in NANO's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 24, 2026
|
|
Cue Biopharma Inc
NASDAQ:CUE
|
1-for-30
/30
|
0.5542 16.626 USD | 17.695 17.695 USD |
|
Apr 24, 2026
|
|
Medical Data Vision Co Ltd
TSE:3902
|
2-for-7253607
/3626803.5
|
1684 1684 JPY | N/A |
|
Apr 24, 2026
|
T
|
Trillion Energy International Inc
CNSX:TCF
|
1-for-5
/5
|
0.2 0.2 CAD | 0.18 0.18 CAD |
|
Apr 24, 2026
|
E
|
ESGL Holdings Ltd
NASDAQ:ESGL
|
1-for-3
/3
|
2.35 7.05 USD | 2.93 2.93 USD |
|
Apr 24, 2026
|
|
Metro Mining Ltd
ASX:MMI
|
1-for-20
/20
|
0.067 1.34 AUD | 1.3 1.3 AUD |
CUE
3902
MMI
Nanobiotix SA
Glance View
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
